*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Tough break for the Competition Council! The Paris Court of Appeal comes to effect, in a judgment delivered yesterday, 8 April 2008, in which it was held, after having reversed Decision No. 07-D-09, rendered on March 14, 2007, that it was not determined that GlaxoSmithKline Laboratory had violated the provisions of the Articles L.420-2 of the Commercial Code and 82 of the EC Treaty. It will be remembered that in this decision, the Competition Council had for the first time issued a conviction for predatory pricing on the basis of the prohibition of abuse of a dominant position, sanctioning the laboratory GlaxoSmithKline in the amount of €10 million for
ALERTS : UNILATERAL PRACTICES - ABUSE OF DOMINANCE - PREDATORY PRICING - FINE - PHARMACEUTICAL INDUSTRY - APPEAL
Predatory pricing: The Paris Court of Appeal severely condemns the Competition Authority’s analysis taking into account the company’s reputation building and thus fining predatory pricing (GSK)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.